Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Updated results from phase III EXTEND clinical trial of pixantrone released

Updated results from phase III EXTEND clinical trial of pixantrone released

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech submits sBLAs to the FDA for Avastin

Genentech submits sBLAs to the FDA for Avastin

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Eisai reports global Phase III study results of eribulin mesylate

Eisai reports global Phase III study results of eribulin mesylate

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

Rituxan's sBLA receives a Complete Response from the FDA

Rituxan's sBLA receives a Complete Response from the FDA

Breast cancer patients who achieve pathological complete response have better outcomes

Breast cancer patients who achieve pathological complete response have better outcomes

Orphan drug designation for pixantrone applied by Cell Therapeutics

Orphan drug designation for pixantrone applied by Cell Therapeutics

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

Phase III EXTEND trial results of pixantrone announced

Phase III EXTEND trial results of pixantrone announced